Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines

Research output: Contribution to journalReviewpeer-review

Harvard

Wirth, A, Mikhaeel, NG, Aleman, BMP, Pinnix, CC, Constine, LS, Ricardi, U, Illidge, TM, Eich, HT, Hoppe, BS, Dabaja, B, Ng, AK, Kirova, Y, Berthelsen, AK, Dieckmann, K, Yahalom, J & Specht, L 2020, 'Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines', International Journal of Radiation Oncology Biology Physics, vol. 107, no. 5, pp. 909-933. https://doi.org/10.1016/j.ijrobp.2020.03.019

APA

Wirth, A., Mikhaeel, N. G., Aleman, B. M. P., Pinnix, C. C., Constine, L. S., Ricardi, U., Illidge, T. M., Eich, H. T., Hoppe, B. S., Dabaja, B., Ng, A. K., Kirova, Y., Berthelsen, A. K., Dieckmann, K., Yahalom, J., & Specht, L. (2020). Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology Biology Physics, 107(5), 909-933. https://doi.org/10.1016/j.ijrobp.2020.03.019

CBE

Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U, Illidge TM, Eich HT, Hoppe BS, Dabaja B, Ng AK, Kirova Y, Berthelsen AK, Dieckmann K, Yahalom J, Specht L. 2020. Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology Biology Physics. 107(5):909-933. https://doi.org/10.1016/j.ijrobp.2020.03.019

MLA

Vancouver

Author

Wirth, Andrew ; Mikhaeel, N George ; Aleman, Berthe M P ; Pinnix, Chelsea C ; Constine, Louis S ; Ricardi, Umberto ; Illidge, Tim M ; Eich, Hans Theodor ; Hoppe, Bradford S ; Dabaja, Bouthaina ; Ng, Andrea K ; Kirova, Youlia ; Berthelsen, Anne Kiil ; Dieckmann, Karin ; Yahalom, Joachim ; Specht, Lena. / Involved Site Radiation Therapy in Adult Lymphomas : An Overview of International Lymphoma Radiation Oncology Group Guidelines. In: International Journal of Radiation Oncology Biology Physics. 2020 ; Vol. 107, No. 5. pp. 909-933.

Bibtex

@article{de62000e8f0c4d9799953248f9aee0ce,
title = "Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines",
abstract = "Involved node radiation therapy for lymphoma was introduced with the aim of using the smallest effective treatment volume, individualized to the patient's disease distribution, to avoid the potentially unnecessary normal tissue exposure and toxicity risks associated with traditional involved field radiation therapy. The successful implementation of involved node radiation therapy requires optimal imaging and precise coregistration of baseline imaging with the radiation therapy planning computed tomography scan. Limitations of baseline imaging, changes in patient position, and anatomic changes after chemotherapy may make this difficult in routine practice. Involved site radiation therapy (ISRT) was introduced by the International Lymphoma Radiation Oncology Group as a slightly larger treated volume, intended to allow for commonly encountered uncertainties. In addition to imaging considerations, the optimal ISRT treatment volume also depends on disease histology, stage, nodal or extranodal location, and the type and efficacy of systemic therapy, which in turn influence the distribution of macroscopic and potential subclinical disease. This article presents a systematic overview of ISRT, updating key evidence and highlighting differences in the application of ISRT across the lymphoma clinical spectrum.",
author = "Andrew Wirth and Mikhaeel, {N George} and Aleman, {Berthe M P} and Pinnix, {Chelsea C} and Constine, {Louis S} and Umberto Ricardi and Illidge, {Tim M} and Eich, {Hans Theodor} and Hoppe, {Bradford S} and Bouthaina Dabaja and Ng, {Andrea K} and Youlia Kirova and Berthelsen, {Anne Kiil} and Karin Dieckmann and Joachim Yahalom and Lena Specht",
note = "Copyright {\textcopyright} 2020 The Author(s). Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = aug,
day = "1",
doi = "10.1016/j.ijrobp.2020.03.019",
language = "English",
volume = "107",
pages = "909--933",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc",
number = "5",

}

RIS

TY - JOUR

T1 - Involved Site Radiation Therapy in Adult Lymphomas

T2 - An Overview of International Lymphoma Radiation Oncology Group Guidelines

AU - Wirth, Andrew

AU - Mikhaeel, N George

AU - Aleman, Berthe M P

AU - Pinnix, Chelsea C

AU - Constine, Louis S

AU - Ricardi, Umberto

AU - Illidge, Tim M

AU - Eich, Hans Theodor

AU - Hoppe, Bradford S

AU - Dabaja, Bouthaina

AU - Ng, Andrea K

AU - Kirova, Youlia

AU - Berthelsen, Anne Kiil

AU - Dieckmann, Karin

AU - Yahalom, Joachim

AU - Specht, Lena

N1 - Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Involved node radiation therapy for lymphoma was introduced with the aim of using the smallest effective treatment volume, individualized to the patient's disease distribution, to avoid the potentially unnecessary normal tissue exposure and toxicity risks associated with traditional involved field radiation therapy. The successful implementation of involved node radiation therapy requires optimal imaging and precise coregistration of baseline imaging with the radiation therapy planning computed tomography scan. Limitations of baseline imaging, changes in patient position, and anatomic changes after chemotherapy may make this difficult in routine practice. Involved site radiation therapy (ISRT) was introduced by the International Lymphoma Radiation Oncology Group as a slightly larger treated volume, intended to allow for commonly encountered uncertainties. In addition to imaging considerations, the optimal ISRT treatment volume also depends on disease histology, stage, nodal or extranodal location, and the type and efficacy of systemic therapy, which in turn influence the distribution of macroscopic and potential subclinical disease. This article presents a systematic overview of ISRT, updating key evidence and highlighting differences in the application of ISRT across the lymphoma clinical spectrum.

AB - Involved node radiation therapy for lymphoma was introduced with the aim of using the smallest effective treatment volume, individualized to the patient's disease distribution, to avoid the potentially unnecessary normal tissue exposure and toxicity risks associated with traditional involved field radiation therapy. The successful implementation of involved node radiation therapy requires optimal imaging and precise coregistration of baseline imaging with the radiation therapy planning computed tomography scan. Limitations of baseline imaging, changes in patient position, and anatomic changes after chemotherapy may make this difficult in routine practice. Involved site radiation therapy (ISRT) was introduced by the International Lymphoma Radiation Oncology Group as a slightly larger treated volume, intended to allow for commonly encountered uncertainties. In addition to imaging considerations, the optimal ISRT treatment volume also depends on disease histology, stage, nodal or extranodal location, and the type and efficacy of systemic therapy, which in turn influence the distribution of macroscopic and potential subclinical disease. This article presents a systematic overview of ISRT, updating key evidence and highlighting differences in the application of ISRT across the lymphoma clinical spectrum.

U2 - 10.1016/j.ijrobp.2020.03.019

DO - 10.1016/j.ijrobp.2020.03.019

M3 - Review

C2 - 32272184

VL - 107

SP - 909

EP - 933

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -

ID: 61016404